Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Somnomed Limited ( (AU:SOM) ) has provided an announcement.
SomnoMed Limited’s quarterly cash flow report reveals a net cash inflow from operating activities, highlighting strong customer receipts despite significant expenditures in manufacturing, staff, and administrative costs. However, the company experienced a net cash outflow in investing and financing activities, resulting in an overall increase in cash and cash equivalents for the period, indicating a stable financial position.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
More about Somnomed Limited
SomnoMed Limited operates in the healthcare industry, specializing in the development and manufacturing of oral appliances for the treatment of sleep-related disorders, primarily obstructive sleep apnea. The company focuses on providing non-invasive solutions to improve patient outcomes and quality of life.
Average Trading Volume: 71,817
Technical Sentiment Signal: Hold
Current Market Cap: A$148M
For an in-depth examination of SOM stock, go to TipRanks’ Overview page.